Italia markets close in 4 hours 45 minutes

FTSE MIB
34.874,77
-524,05(-1,48%)
Dow Jones
40.003,59
+134,19(+0,34%)
Nasdaq
16.685,97
-12,33(-0,07%)
Nikkei 225
39.069,68
+282,30(+0,73%)
Petrolio
79,83
-0,23(-0,29%)
Bitcoin EUR
61.750,85
-362,95(-0,58%)

NBIX Dec 2024 120.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

29,27

0,00

(0,00%)

In data: 12:15PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat